1-hydroxylamino-1-(4'-methoxyphenyl)propane | 52271-34-8

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 1-hydroxylamino-1-(4'-methoxyphenyl)propane
• 英文别名: DL-2-Hydroxylamino-1-(4-methoxy-phenyl)-propan；dl-N-(p-Methoxy-alpha-methylphenethyl)hydroxylamine hydrochloride；N-[1-(4-methoxyphenyl)propan-2-yl]hydroxylamine
• CAS: 52271-34-8
• 化学式: C₁₀H₁₅NO₂
• 分子量: 181.235
• InChiKey: FRVVGSSZWOOTGV-UHFFFAOYSA-N

物化性质

• 沸点：
  321.6±44.0 °C(Predicted)
• 密度：
  1.069±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.8
• 重原子数：
  13
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.4
• 拓扑面积：
  41.5
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  1-hydroxylamino-1-(4'-methoxyphenyl)propane 在 甲醇 作用下， 反应 24.0h， 生成 4-methoxyphenylacetone oxime
  参考文献：
  名称：

  Solvents Inducing Oxidation of Hydroxylamines.

  摘要：

  羟胺在溶解于有机溶剂（如甲醇）后，会逐渐氧化成其肟。1H-NMR 和液相色谱-质谱法（LC-MS）对这一现象进行了跟踪。根据液相色谱-大气压化学电离（APCI）-质谱法质谱图上质子化分子或碎片离子的峰面积估算氧化率。结果表明，羟胺的氧化率取决于溶剂类型。

  DOI：

  10.1248/cpb.50.996
• 作为产物：
  描述：

  4-methoxyphenylacetone oxime 在 platinum(IV) oxide 盐酸 、 氢气 作用下， 以 乙醇 为溶剂， 生成 1-hydroxylamino-1-(4'-methoxyphenyl)propane
  参考文献：
  名称：

  N-烷基羟乙二酰胺及其邻甲基醚的行为和神经药理作用。

  摘要：

  DOI：

  10.1021/jm00325a020

文献信息

• Hydroxylamine derivatives
  申请人：Newron Pharmaceuticals S.p.A.

  公开号：EP1541547A1

  公开（公告）日：2005-06-15

  This invention is related to hydroxylamino derivatives of the following general formula (I) wherein    n is 0, 1 or 2;    R1 and R2, independently of each other, are H, OH or OCH3;    R3 is H or CH3;    R4 is H, C1-C3 straight or branched alkyl or, together with R3, forms a five to seven-membered carbocyclic ring;    and R5 and R6, independently of each other, are H or C1-C5 straight or branched alkyl and the pharmaceutically acceptable salts or prodrug thereof, for the preparation of medicaments useful for the prevention, treatment and diagnosis of CNS degenerative disorders related to protein misfolding and/or misaggregation. The invention also relates to novel compounds included in formula (I), to a method for preparing said compounds and to pharmaceutical compositions containing them.

  这项发明涉及以下一般式（I）的羟胺衍生物， 其中    n为0、1或2；    R1和R2，彼此独立，为H、OH或OCH3；    R3为H或CH3；    R4为H、C1-C3直链或支链烷基，或者与R3一起形成五至七元碳环；    而R5和R6，彼此独立，为H或C1-C5直链或支链烷基 以及其药学上可接受的盐或前药，用于制备用于预防、治疗和诊断与蛋白质错误折叠和/或错误聚集相关的中枢神经系统退行性疾病的药物。 该发明还涉及包含在式（I）中的新化合物，制备这些化合物的方法以及含有它们的药物组合物。
• Solvent‐Free Nucleophilic Addition of N‐Alkylhydroxylamines to Substituted Nitroolefins: Formation of Nitrones by a Tandem process
  作者：Chinnadurai Amutha、Shanmugam Muthusubramanian

  DOI：10.1080/00397910701767031

  日期：2008.1.1

  Abstract Nucleophilic addition of 1‐methyl‐2‐arylethylhydroxylamine to substituted β‐nitrostyrene under solvent‐free conditions has led to unexpected nitrones via a tandem process involving 1,4‐addition and elimination.

  摘要 1-甲基-2-芳乙基羟胺在无溶剂条件下与取代的β-硝基苯乙烯亲核加成，通过涉及1,4-加成和消除的串联过程产生了意想不到的硝酮。
• HYDROXYLAMINE DERIVATIVES
  申请人：CACCIA Carla

  公开号：US20100197799A1

  公开（公告）日：2010-08-05

  This invention is related to hydroxylamino derivatives of the following general formula (I) wherein n is 0, 1 or 2; R 1 and R 2 , independently of each other, are H, OH or OCH 3 ; R 3 is H or CH 3 ; R 4 is H, C 1 -C 3 straight or branched alkyl or, together with R 3 , forms a five to seven-membered carbocyclic ring; and R 5 and R 6 , independently of each other, are H or C 1 -C 5 straight or branched alkyl and the pharmaceutically acceptable salts or prodrug thereof, for the preparation of medicaments useful for the prevention, treatment and diagnosis of CNS degenerative disorders related to protein misfolding and/or misaggregation. The invention also relates to novel compounds included in formula (I), to a method for preparing the compounds and to pharmaceutical compositions containing them.

  本发明涉及以下通式（I）的羟胺衍生物，其中n为0、1或2；R1和R2独立地为H、OH或OCH3；R3为H或CH3；R4为H、C1-C3直链或支链烷基或与R3一起形成五元至七元的碳环；R5和R6独立地为H或C1-C5直链或支链烷基，以及其药学上可接受的盐或前药，用于制备有益于预防、治疗和诊断与蛋白质错折和/或错聚相关的中枢神经系统退行性疾病的药物。本发明还涉及包括式（I）中的新化合物、制备该化合物的方法以及含有它们的药物组合物。
• BARTRA, MARTI;ROMEA, PEDRO;URPI, FELIX;VILARRASA, JAUME, TETRAHEDRON, 46,(1990) N, C. 587-594
  作者：BARTRA, MARTI、ROMEA, PEDRO、URPI, FELIX、VILARRASA, JAUME

  DOI：——

  日期：——
• PROPELLANT-FREE FORMULATION FOR INHALATION
  申请人：Huang Cai Gu

  公开号：US20210205223A1

  公开（公告）日：2021-07-08

  The present invention provides a propellant-free pharmaceutical formulation and a method for administering the pharmaceutical formulation by nebulizing the pharmaceutical formulation in an inhaler. The propellant-free pharmaceutical formulation comprises: (a) glycopyrronium or a salt thereof; (b) formoterol or a salt thereof; (c) a pharmacologically acceptable stabilizer; (d) a pharmacologically acceptable preservative; and (d) a solvent. Additionally, the present invention provides the use of a combination product comprising glycopyrronium or a salt thereof and formoterol or a salt thereof for the prevention or treatment of chronic obstructive pulmonary disease (COPD) and other respiratory diseases.